The experimental and computational analyses generated by the DECODE platforms provide two key codes that fundamentally define a T cell: 
  • Antigen codes comprised of peptide sequences presented on patient-specific tumor MHC 
  • TCR codes comprising TCR sequences, which interact with defined antigen codes 
Our DECODE platforms generate billions of data points from hundreds of thousands of T cells to map the T cell response of a patient. These immune maps connect antigen presentation to TCR clonotype and include information on T cell phenotype. Maps from multiple patients reveal powerful convergences of immune codes that can be harnessed to understand immune biology and drive the development of new, potentially curative medicines.
Repertoire uses converged immune maps to identify both antigen codes and TCR codes against which to DEPLOY therapeutic modalities that are designed for specific disease indications such as cancer, autoimmunity, or infectious disease.

Therapeutic modalities could consist of adoptive cell therapies developed through rational engineering, peptide targeted vaccines demonstrated to optimally stimulate the immune system, or protein mimetics to address codes that may be absent from a patient’s immune repertoire.

Our initial focus is to DEPLOY next generation PRIME cell therapies with TETHERED immunomodulators that are locally and sustainably administered. This approach enables Repertoire to use powerful immune agonists to safely drive productive immune biology in patient’s tumors.

In order to kill tumors, T cells must traffic to the tumor and be supported in immune-suppressive environments. However, the powerful immunomodulators that support T cell function and remodel the tumor microenvironment are toxic when given systemically. 

To safely leverage the potent immune-activating potential of these molecules, Repertoire has developed the unique TETHER immune agonist delivery platform utilizing T cells to target immune agonists to tumors while minimizing systemic exposure.

Repertoire’s initial TETHER payloads include:
  • ANCHORIL-15 to improve T cell survival, expansion, and memory
  • BRIDGEIL-12 to promote immune cell effector function and antigen presentation 
  • CLOUDTLR-7 agonist to promote broader adaptive immunity against the tumor
Below you can learn more about ANCHOR, BRIDGE and CLOUD  and how they are combined with our advanced STREAM™ biomanufacturing platform.
Our initial focus combines multiple technologies to create next generation PRIME cell therapies against cancer.Repertoire DEPLOYS immune codes into multiclonal T cell therapeutics generated from a patient’s own immune cells. CD4 and CD8 T cells that recognize multiple tumor-associated antigens are expanded using our advanced STREAM™ biomanufacturing platform, and are then combined with immune stimulatory drugs using our TETHER™ technology.

The resulting PRIME T cell product drives a regulated immune response that integrates with the patient’s natural immune system and delivers controlled and sustained immune activation in the tumor with limited off-target activity.using our TETHER™ technology.

The result is a regulated immune response that integrates with the patient’s natural immune system and delivers controlled and sustained immune activation in the tumor with limited off-target activity. 
Learn more about ANCHOR, BRIDGE and CLOUD immunomodulator delivery technologies, PRIME T cells, and how these are applied in our advanced STREAM™ biomanufacturing platform.
Personalized Biomanufacturing
Repertoire STREAM personalized cell biomanufacturing trains a patient’s T cells to target tumor antigens.
The STREAM biomanufacturing platform uses a proprietary dendritic cell priming technology to naturally expand a patient’s own tumor reactive T cells in an HLA independent manner. High process yields and the ability to freeze the resulting drug product enable repeat dosing for continued immune therapy, while automation and Single Use technologies support rapid, on-demand manufacturing. To enable the rapid deployment of novel immune coded therapies to patients, the STREAM platform features a modular production system that accelerates new products into the clinic.
T Cell Products
PRIME T Cells are engineered for enhanced anti-tumor activity with TETHER immunomodulators.
PRIME T cells are natural, multiclonal CD8 and CD4 cells featuring an optimized phenotype and high antigen-specific reactivity to multiple tumor antigens. PRIME T cells can be combined with tethered immunomodulators to make designer immunotherapies that target multiple antigens and provide T cell support and tumor microenvironment remodeling to enhance immune function.
Directing immune power to harness potent immune modulators
Immune agonists such as cytokines or toll-like receptor agonists are critical for effective cell therapy for cancer. Such agonists are limited, however, by high systemic toxicity. Repertoire's TETHER Immunomodulator platform enables controlled and directed immune agonist activity to safely harness their powerful biology for cell therapy.
The ANCHOR Nanogel Technology enables delivery of biologic immune agonists such as cytokines for autocrine immune cell stimulation. Immune agonists are formulated into a nanogels and tethered to T cells prior to adoptive cell therapy, where they slowly release their cargo for localized activity on the tethered cell. Lead: DeepIL-15 for T cell proliferation and memory.
The BRIDGE Cytokine Technology enables delivery of protein-based immune agonists for combined autocrine and paracrine stimulation of the immune system. BRIDGE cytokines are tethered to the surface of the T cell prior to adoptive cell therapy where they then act in an autocrine manner on the tethered cell or undergo time-dependent release for paracrine activity on neighboring cells. 

TetheredIL-12 to activate innate and adaptive immunity in the tumor.
The CLOUD Lipid Technology enables delivery of small molecule immune modulators with cell therapy. The small molecule immune modulators are formulated into a liposomal nanoparticle that is optimized for delivery inside of the T cell. The cell then acts as a living carrier of the drug and releases it outside of the cell over two weeks. Lead: DeepTLR to activate antigen presenting cells in tumor and promote epitope spreading.